Showing results (761-770 of 772) with videos related to

Sort By:
Pageof 78
Science Translational Medicine|December 18, 2024
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronKyle W Sloop, Amy L Cox, David B Wainscott, et al.
Cancer Research|August 17, 2006
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 yearsKathleen E Malone, Janet R Daling, David R Doody, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
European Journal of Heart Failure|December 21, 2010
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyThomas Eschenhagen, Thomas Force, Michael S Ewer, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
Swiss Medical Weekly|August 14, 2025
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis NetworkMax J Rieger, Andreas J Flammer, Sabine Gerull, et al.
Placenta|February 24, 2015
IFPA meeting 2014 workshop report: Animal models to study pregnancy pathologies; new approaches to study human placental exposure to xenobiotics; biomarkers of pregnancy pathologies; placental genetics and epigenetics; the placenta and stillbirth and fetal growth restrictionS Barbaux, J J H M Erwich, P O Favaron, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 5, 2016
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or TachyphylaxisKjell A Svensson, Beverly A Heinz, John M Schaus, et al.
European Journal of Heart Failure|October 2, 2020
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Christian Mueller, Jelena Čelutkienė, et al.
The New England Journal of Medicine|November 13, 2020
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart FailureJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Pageof 78